Proffitt & Goodson Inc. Has $918,000 Stock Position in iShares Biotechnology ETF (NASDAQ:IBB)

Proffitt & Goodson Inc. reduced its position in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 1.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,946 shares of the financial services provider’s stock after selling 113 shares during the period. Proffitt & Goodson Inc.’s holdings in iShares Biotechnology ETF were worth $918,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Huntington National Bank increased its holdings in shares of iShares Biotechnology ETF by 17.9% during the third quarter. Huntington National Bank now owns 1,054 shares of the financial services provider’s stock worth $153,000 after buying an additional 160 shares in the last quarter. National Bank of Canada FI grew its stake in shares of iShares Biotechnology ETF by 5.9% in the third quarter. National Bank of Canada FI now owns 4,124 shares of the financial services provider’s stock worth $600,000 after purchasing an additional 229 shares during the last quarter. Avior Wealth Management LLC grew its stake in shares of iShares Biotechnology ETF by 438.2% in the third quarter. Avior Wealth Management LLC now owns 3,229 shares of the financial services provider’s stock worth $470,000 after purchasing an additional 2,629 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its stake in shares of iShares Biotechnology ETF by 32.9% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock worth $96,533,000 after purchasing an additional 164,000 shares during the last quarter. Finally, Main Management ETF Advisors LLC grew its stake in shares of iShares Biotechnology ETF by 2.5% in the third quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after purchasing an additional 14,535 shares during the last quarter. 62.45% of the stock is currently owned by institutional investors and hedge funds.

iShares Biotechnology ETF Price Performance

Shares of iShares Biotechnology ETF stock opened at $137.03 on Friday. The company’s fifty day moving average is $135.82 and its 200 day moving average is $140.68. iShares Biotechnology ETF has a twelve month low of $123.60 and a twelve month high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The company also recently declared a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were given a dividend of $0.0624 per share. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.